Last reviewed · How we verify

CONRAD — Portfolio Competitive Intelligence Brief

CONRAD pipeline: 1 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 3 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Estradiol vaginal cream Estradiol vaginal cream marketed Estrogen replacement therapy Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Gynecology / Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Mylan Pharmaceuticals Inc · 1 shared drug class
  2. Pfizer · 1 shared drug class
  3. University of California, Irvine · 1 shared drug class
  4. University of Virginia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CONRAD:

Cite this brief

Drug Landscape (2026). CONRAD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/conrad. Accessed 2026-05-13.

Related